|
IL-5 |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
< |
< |
|
> |
97 |
N.I. |
Prakash et al., 2006, J Infect Dis |
Link |
|
IL-5 |
Plasmodium falciparum |
Serum (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
IL-5 |
Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
> |
99 |
HC were the same patients 3 weeks after treatment |
Abeles et al., 2013, Am J Trop Med Hyg |
Link |
|
IL-6 |
Plasmodium falciparum |
CSF |
|
|
|
|
> |
|
|
|
|
84 |
CM patients: CSF < Serum |
John et al., 2008, Am J Trop Med Hyg |
Link |
|
IL-6 |
Plasmodium falciparum |
CSF (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
= |
|
|
|
|
= |
|
|
> |
86 |
N.I. |
Baptista et al., 1997, Trop Med Int Health |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
< |
< |
|
> |
97 |
endemic HC < non-endemic HC |
Prakash et al., 2006, J Infect Dis |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
= |
|
|
|
|
|
|
|
41 |
3 days after treatment: levels ↓ in survivors but not in patients who died with SM† > SM |
Sarthou et al., 1997, Infect Immun |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
> |
|
|
38 |
Levels ↓ during treatment; + correlation with IL-10; - correlation with protein C |
Vogetseder et al., 2004, Trop Med Int Health |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
47 |
SM > HC; + correlation with Bb |
Wenisch et al., 1997, Clin Immunol Immunopathol |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
54 |
SM > NM, HC; no correlation with big endothelin-1 |
Wenisch et al., 1996, J Infect Dis |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
|
|
|
|
48 |
SM > HC; plasma levels ↓ during treatment |
Wenisch et al., 1999, J Infect Dis |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
> |
<* |
|
|
|
|
|
|
287 |
cerebral symptoms < cerebral symptoms + coma + MOD; + correlation with IL-10, venous lactate, standard base deficit, respiratory rate and parasite count; high levels associated with hyperparasitemia, jaundice and hemodynamic shock |
Day et al., 1999, J Infect Dis |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
> |
16 |
N.I. |
Dekker et al., 1997, Am J Physiol |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
> |
|
|
145 |
+ correlation with body temperature |
Perera et al., 2013, Pathog Glob Health |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
= |
|
|
|
|
|
|
|
236 |
CM + RD, hyperparasitemia/prostration > RD; + correlation with plasma IL-10 |
English et al., 1997, QJM |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
58 |
CM, NCSM > HC |
Larkin et al., 2009 PLoS Pathog |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
= |
|
97 |
N.I. |
Jakobsen et al., 1994, Clin Exp Immunol |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
> |
56 |
SM > HC |
Löwenberg et al., 2010, Thromb Heamost |
Link |
|
IL-6 |
Plasmodium falciparum |
Plasma/Serum |
|
|
= |
|
|
< |
≤ |
> |
> |
179 |
Plasma: SMA < UM; serum: SMA = UM; CM = NM/HC; SMA > NM/HC; + correlation with serum IL-1b, GM-CSF and TNF in all patient groups (UM, CM, and SMA) and with IL-10 in UM and SMA patients (but not in CM patients) |
Burté et al., 2013, Blood |
Link |
|
IL-6 |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
> |
39 |
+ correlation with serum TNF-a and fever |
Clark et al., 1992, Trans R Soc Trop Med Hyg |
Link |
|
IL-6 |
Plasmodium falciparum |
Serum |
> |
|
|
|
|
= |
|
|
> |
217 |
- correlation with platelet count |
John et al., 2006, J Infect Dis |
Link |
|
IL-6 |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
83 |
SM > HC; plasma levels ↓ after treatment; + correlation with sCD14 |
Wenisch et al., 1996, Clin Exp Immunol |
Link |
|
IL-6 |
Plasmodium falciparum |
Serum |
|
= |
> |
|
|
|
> |
|
> |
748 |
N.I. |
Lyke et al., 2004, Infect Immun |
Link |
|
IL-6 |
Plasmodium falciparum |
Serum |
> |
|
|
|
|
= |
|
|
> |
242 |
CM > AM |
Jakobsen et al., 1994, Infect Immun |
Link |
|
IL-6 |
Plasmodium falciparum |
Serum (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
IL-6 |
Plasmodium falciparum, Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
> |
53 |
P. falciparum (UM + 3SM), P. vivax > HC; - correlation with ADAMTS13 activity and platelet count |
De Mast et al., 2009, Am J Trop Med Hyg |
Link |
|
IL-6 |
Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
> |
99 |
HC were the same patients 3 weeks after treatment; nontransmitters >(ns) transmitters |
Abeles et al., 2013, Am J Trop Med Hyg |
Link |
|
IL-6 |
Plasmodium vivax |
Serum |
|
|
|
|
|
|
|
|
> |
41 |
Thrombocytopenic patients > non-thrombocytopenic patients; - correlation with platelet counts |
Coelho et al., 2013, PLoS One |
Link |
|
IL-6:IL-10 |
Plasmodium falciparum |
Plasma |
|
> |
< |
|
|
|
|
|
|
287 |
N.I. |
Day et al., 1999, J Infect Dis |
Link |
|
IL-6:IL-10 |
Plasmodium falciparum |
Serum |
|
= |
|
|
|
|
|
|
|
748 |
N.I. |
Lyke et al., 2004, Infect Immun |
Link |
|
IL-6Rb (gp130) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
|
|
|
|
48 |
SM = HC |
Wenisch et al., 1999, J Infect Dis |
Link |
|
IL-7 |
Plasmodium falciparum |
CSF (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
IL-7 |
Plasmodium falciparum |
Serum (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
IL-9 |
Plasmodium falciparum |
CSF (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
IL-9 |
Plasmodium falciparum |
Serum (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
Inorganic phosphate |
Plasmodium falciparum |
Plasma |
|
> |
|
|
|
|
|
|
|
268 |
+ correlation with strong ion gap (representing unmeasured anions) |
Dondorp et al., 2004, Crit Care Med |
Link |
|
Insulin |
N.I. |
Serum |
|
|
|
|
|
|
|
|
|
186 |
SM = NM |
Kawo et al., 1990, Lancet |
Link |
|
Insulin |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
= |
|
|
= |
25 |
N.I. |
Blümer et al., 2005, Metabolism |
Link |
|
Insulin |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
13 |
CM = HC |
Van Thien et al., 2001, QJM |
Link |
|
Insulin |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
= |
16 |
N.I. |
Dekker et al., 1997, Am J Physiol |
Link |
|
Isoleucine |
N.I. |
Plasma |
|
|
|
|
|
= |
|
|
= |
126 |
N.I. |
Lopansri et al., 2006, Infect Immun |
Link |
|
Isoleucine |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
50 |
Malaria (UM + CM) = HC |
Enwonwu et al., 1999, QJM |
Link |
|
Kallikrein inhibitor |
Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
|
12 |
P. vivax = HC |
Roy et al., 1988, Indian J Malariol |
Link |
|
Kininase I |
Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
|
12 |
P. vivax > HC |
Roy et al., 1988, Indian J Malariol |
Link |
|
Kynurenic acid (KA) |
Plasmodium falciparum |
CSF |
|
= |
= |
|
|
|
|
|
|
281 |
SM = NM-NCNS |
Medana et al., 2002, J Infect Dis |
Link |
|
Kynurenic acid (KA) |
Plasmodium falciparum |
CSF |
|
|
|
|
|
> |
|
|
|
120 |
KA malawian children with CM > KA vietnamese adults with SM; + correlation with fever duration and AST; - correlation with hematocrit |
Medana et al., 2003, J Infect Dis |
Link |
|
L-arg:ADMA |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
< |
|
< |
146 |
Levels ↑ after start of treatment (SM survivors) |
Yeo et al., 2010, PLoS Pathog |
Link |
|
L-arg:ornithine |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
= |
147 |
N.I. |
Yeo et al., 2007, J Exp Med |
Link |
|
L-Phenylalanine |
N.I. |
Plasma |
> |
|
|
|
|
|
> |
|
> |
156 |
N.I. |
Lopansri et al., 2006, Infect Immun |
Link |
|
L-Phenylalanine |
N.I. |
Plasma |
|
|
|
|
|
> |
|
|
> |
126 |
N.I. |
Lopansri et al., 2006, Infect Immun |
Link |
|
L-Phenylalanine |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
50 |
Malaria (UM + CM) > HC; CM = hyperparasitemia, CM > NCSM patients with premedication with folate; similar apparent Km and ↑ (calculated) brain uptake by BBB transporter for malaria group compared with HC |
Enwonwu et al., 1999, QJM |
Link |
|
Lactate |
N.I. |
Blood |
|
|
|
|
|
|
|
|
|
186 |
SM > NM |
Kawo et al., 1990, Lancet |
Link |
|
Lactate |
Plasmodium falciparum |
Blood |
|
> |
|
|
|
|
|
|
|
115 |
Levels ↓ rapidly in survivors whereas levels ↓ slowly or even ↑ in fatal cases; concentrations between 4h and 24h were good predictors of a fatal outcome; + correlation with mortality, pyruvate concentrations, CSF lactate concentrations, blood TNF-a and IL-1a; - correlation with blood glucose concentration and clinical parameters of recovery; logistic regression indicated venous lactate ≥ 5 mmol/L (for CM CSF lactate > 4.5 mmol/L) as an independently predictive of fatal outcome |
Krishna et al., 1994, Trans R Soc Trop Med Hyg |
Link |
|
Lactate |
Plasmodium falciparum |
Blood |
|
|
|
|
|
|
> |
|
|
118 |
SM > NM; - correlation with coma score and fatal outcome |
Agbenyega et al., 1997, Trans R Soc Trop Med Hyg |
Link |
|
Lactate |
Plasmodium falciparum |
Blood |
|
|
|
|
|
|
> |
|
|
97 |
levels ↓ during treatment; - correlation with improvement of endothelial function (RH-PAT index) |
Yeo et al., 2008, J Infect Dis |
Link |
|
Lactate |
Plasmodium falciparum |
Blood |
|
|
|
|
|
|
|
|
|
69 |
SM > HC (recoverd from UM) |
Sasi et al., 2007, Am J Trop Med Hyg |
Link |
|
Lactate |
Plasmodium falciparum |
CSF |
|
> |
|
|
|
|
|
|
|
281 |
+ correlation with jaundice, shock, renal failure and pulmonary edema |
Medana et al., 2002, J Infect Dis |
Link |
|
Lactate |
Plasmodium falciparum |
CSF |
|
> |
|
|
|
|
|
|
|
18 |
N.I. |
Agbenyega et al., 1997, Trans R Soc Trop Med Hyg |
Link |
|
Lactate |
Plasmodium falciparum |
CSF |
|
|
|
|
|
|
|
|
|
23 |
CM patients had ↑ levels during coma on admission compared with after recovery from coma |
Davis et al., 1995, J Infect |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
> |
|
|
|
|
|
|
|
306 |
SM† > SMseq; CM + RD, RD > CM, hyperparasitemia/prostration |
English et al., 1997, QJM |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
> |
|
|
|
|
|
|
|
400 |
Hyperlactatemia is a good predictor of a fatal outcome; + correlation with heart rate, NT-proBNT, H-FABP, myoglobin; - correlation with systolic and diastolic blood pressure |
Ehrhardt et al., 2005, Microbes Infect |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
|
|
|
|
253 |
N.I. |
Hollestelle et al., 2006, Br J Haematol |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
> |
|
|
147 |
N.I. |
Yeo et al., 2007, J Exp Med |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
> |
|
|
|
|
|
|
|
24 |
N.I. |
Dondorp et al., 1998, Am J Trop Med Hyg |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
> |
|
|
127 |
+ correlation with ADMA and SDMA |
Yeo et al., 2010, PLoS Pathog |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
> |
|
|
|
|
|
|
|
268 |
N.I. |
Dondorp et al., 2004, Crit Care Med |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
35 |
SM > HC |
Davis et al., 1995, J Infect |
Link |
|
Lactate |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
13 |
CM > HC |
Van Thien et al., 2001, QJM |
Link |
|
Lactate dehydrogenase (LDH) |
Plasmodium falciparum |
CSF |
|
|
|
< |
> |
|
|
|
|
46 |
CSF:serum LDH ratio was significantly ↑ in CM patients compared to NM-NCNS patients |
Jakka et al., 2006, Cerebrospinal Fluid Res |
Link |
|
Lactate dehydrogenase (LDH) |
Plasmodium falciparum |
Plasma |
|
> |
|
|
|
|
> |
|
> |
147 |
SM > HC; + correlation with plasma arginase activity, sICAM-1 and sE-selectin |
Yeo et al., 2007, J Exp Med |
Link |
|
Lactate dehydrogenase (LDH) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
> |
|
|
97 |
N.I. |
Yeo et al., 2008, J Infect Dis |
Link |
|
Lactate dehydrogenase (LDH) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
46 |
CM = NM (NM patients with viral encephalitis = NM patients without); CSF/serum LDH ratio was significantly ↑ in CM patients compared to NM patients without viral encephalitis |
Jakka et al., 2006, Cerebrospinal Fluid Res |
Link |
|
Lactate dehydrogenase (LDH) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
> |
152 |
N.I. |
Garba et al., 2005, Singapore Med J |
Link |
|
Lactate:pyruvate |
Plasmodium falciparum |
CSF |
|
= |
= |
|
|
|
|
|
|
281 |
Elevated in all studied groups |
Medana et al., 2002, J Infect Dis |
Link |
|
LDL-cholesterol |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
= |
74 |
N.I. |
Djoumessi et al., 1989, Pathol Biol (Paris) |
Link |
|
LDL-cholesterol |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
35 |
SM < HC |
Davis et al., 1995, J Infect |
Link |
|
LDL-cholesterol |
Plasmodium falciparum, Plasmodium vivax |
Serum |
|
|
|
|
|
|
|
|
< |
28 |
P. falciparum = P. vivax; + correlation with plasma lyso-PAF |
Davis et al., 1993, J Infect |
Link |
|
LDL-cholesterol |
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale |
Plasma |
|
|
|
|
|
|
|
|
< |
16 |
Levels were normalized at follow-up after 2 weeks |
Nilsson-Ehle et al., 1990, J Intern Med |
Link |
|
Leucine |
N.I. |
Plasma |
|
|
|
|
|
> |
|
|
= |
126 |
N.I. |
Lopansri et al., 2006, Infect Immun |
Link |
|
Leucine |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
50 |
Malaria (UM + CM) = HC |
Enwonwu et al., 1999, QJM |
Link |
|
Leukemia inhibitory factor (LIF) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
|
|
|
|
48 |
CM = RF = NCSM = HC; - correlation with parasitemia, TNF-a, sTNFR1 and IL-6; + correlation with platelet count and fever before treatment |
Wenisch et al., 1999, J Infect Dis |
Link |
|
LT |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
> |
|
97 |
N.I. |
Jakobsen et al., 1994, Clin Exp Immunol |
Link |
|
LT |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
> |
39 |
N.I. |
Clark et al., 1992, Trans R Soc Trop Med Hyg |
Link |
|
Lysine |
N.I. |
Plasma |
|
|
|
|
|
= |
|
|
< |
126 |
N.I. |
Lopansri et al., 2006, Infect Immun |
Link |
|
Lysine |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
50 |
Malaria (UM + CM) = HC |
Enwonwu et al., 1999, QJM |
Link |
|
Lyso-platelet activating factor (lyso-PAF) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
35 |
SM < HC; levels increased during therapy for CM patients; - correlation with parasitemia and serum triglyceride concentration |
Davis et al., 1995, J Infect |
Link |
|
Lyso-platelet activating factor (lyso-PAF) |
Plasmodium falciparum, Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
< |
28 |
P. falciparum = P. vivax; + correlation with serum total, LDL and HDL cholesterol |
Davis et al., 1993, J Infect |
Link |
|
Lysozyme |
Plasmodium falciparum, Plasmodium vivax |
Plasma |
|
|
|
|
|
|
> |
= |
|
65 |
+ correlation with HNL |
Mohammed et al., 2003, Acta Trop |
Link |
|
m-(mu)Calpain (I) |
Plasmodium falciparum |
Brain (PM)-IHC |
|
|
|
|
|
|
|
|
|
41 |
Axons: SM = NM-CNS → extent and distribution staining differed; + correlation with b-APP; Neurons: SM > NM-NCNS (nuclear staining); CM = NCSM = NM-CNS; Glia: CM > NCSM = NM-NCNS = NM-CNS; Endothelial cells: CM = NCSM = NM-CNS |
Medana et al., 2007, Neuropathol Appl Neurobiol |
Link |
|
m-Calpain (II) |
Plasmodium falciparum |
Brain (PM)-IHC |
|
|
|
|
|
|
|
|
|
41 |
Axons: SM = NM-CNS → extent and distribution staining differed; + correlation with b-APP; Neurons: SM > NM-NCNS (diffuse cytoplasmic staining); CM = NCSM = NM-CNS; Endothelial cells: CM = NCSM = NM-CNS |
Medana et al., 2007, Neuropathol Appl Neurobiol |
Link |
|
Macrophage scavenger receptor (MSR) |
Plasmodium falciparum |
Brain (PM)-IHC |
|
|
= |
|
> |
|
|
|
|
24 |
N.I. |
Brown et al., 1999, Neuropathol Appl Neurobiol |
Link |
|
Magnesium |
Plasmodium falciparum |
Plasma |
|
> |
|
|
|
|
|
|
|
268 |
N.I. |
Dondorp et al., 2004, Crit Care Med |
Link |
|
Mannose-binding lectin (MBL) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
|
200 |
Incidence of low MBL and corresponding mutations in MBL gene: SM>UM |
Luty et al., 1998, J Infect Dis |
Link |
|
Methemoglobin |
Plasmodium falciparum |
Finger pulse co-oximeter measurement |
|
> |
|
|
|
|
= |
= |
> |
117 |
SM = NM |
Yeo et al., 2013, J Infect Dis |
Link |
|
Methionine |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
50 |
Malaria (UM + CM) = HC |
Enwonwu et al., 1999, QJM |
Link |
|
Microparticles (endothelial cell-derived) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
> |
> |
|
n.s. |
158 |
CM, SM > HC; (partial) normalisation at patient discharge; + correlation with TNF |
Sahu et al., 2013, Inf. Immun.; also Sahu et al., 2013, Human Immunol |
Link |
|
Microparticles (erythrocyte-derived) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
> |
> |
|
n.s. |
158 |
CM, SM > HC; (partial) normalisation at patient discharge; + correlation with parasite density and TNF; - correlation with hemoglobin and erythrocyte count |
Sahu et al., 2013, Inf. Immun.; also Sahu et al., 2013, Human Immunol |
Link |
|
Microparticles (platelet-derived) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
> |
> |
|
n.s. |
158 |
CM, SM > HC; (partial) normalisation at patient discharge; - correlation with platelet count; + correlation with TNF |
Sahu et al., 2013, Inf. Immun.; also Sahu et al., 2013, Human Immunol |
Link |
|
Microparticles (total) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
> |
> |
|
n.s. |
158 |
CM, SM > HC; The -477C/T and -320G/C ABCA1 promoter polymorhisms are associated with an increase in plasma microparticle numbers and with susceptibility to SM; (partial) normalisation at patient discharge; + correlation with parasite density; - correlation with hemoglobin |
Sahu et al., 2013, Inf. Immun.; also Sahu et al., 2013, Human Immunol |
Link |